Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News
July 16th 2025

Review Highlights Gaps in Transition From Pediatric to Adult MS Care

July 8th 2025

Multinational Study Highlights COVID-19 Vaccine Safety in MS

July 7th 2025

The Rise of Precision Monoclonal Antibodies in Treating MS

April 9th 2025

Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

March 14th 2025

5 Ongoing Clinical Trials Evaluating Treatment for MS

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Video Interviews
View All
July 18th 2025

Redefining Value: What Payers Want From Comprehensive MS Treatments

July 18th 2025

Bridging the Gaps: BTK Inhibitors and the Future of MS Care

July 11th 2025

Aligning Evidence With Access: Disability Outcomes, Data, and Payer Decision-Making

July 4th 2025

Closing the Gaps: Therapeutic Performance and the Promise of Innovation

July 4th 2025

Digging Deeper: Mechanisms of Progression and the Case for a Dual Therapeutic Approach

June 27th 2025

Measuring What Matters: Evidence and End Points That Define Disability in MS

June 27th 2025

Understanding PIRA and Its Clinical Significance in MS

July 24th 2024

Multiple Sclerosis: Looking Toward the Future

July 24th 2024

Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

July 16th 2024

Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

Podcasts
View All
November 30th 2021

Millennials With Multiple Sclerosis: Are They Different or Has Medicine Evolved?

December 1st 2019

Podcast: This Week in Managed Care—Challenges of Rural Healthcare Delivery and Other Health News

September 1st 2019

Podcast: This Week in Managed Care—Opioid Ruling and Settlement, and Other Health News

Continuing Medical Education
View All
July 18th 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
July 18th 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
July 18th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 18th 2025

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

August 21, 2025 | 1:00 PM ET & 8:00 PM ET
July 18th 2025

Overview and Burden of Migraine

0.5 Credit / Neurology
July 18th 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology
July 18th 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology
July 18th 2025

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

1.5 Credits / Neurology, Psychiatry
July 18th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Kavita Nair Q&A - Maks_Lab - stock.adobe.com.jpeg
March 12th 2025

Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

Christina Mattina Kavita V. Nair, PhD
In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.
Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com
January 9th 2025

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

AJMC Contributor
Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Ocrelizumab is a monoclonal antibody that targets CD20 on B cells | image credit: molekuul.be - stock.adobe.com
January 8th 2025

Subcutaneous Ocrelizumab Well Tolerated in Patients With MS

Karen Jacobson-Sive
Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis (RMS/PPMS).
Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
January 6th 2025

Pain May Be Indicator of MS Prior to Disease Onset: Study

AJMC Contributor
Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.
Better understanding the vascular sequelae of MS may similarly unlock predictive insights for people with MS, according to investigators. | Image credit: Elena - stock.adobe.com
January 3rd 2025

Meta-Analysis: Vascular Function Worse in People With MS

Jared Kaltwasser
The differences did not appear to be associated with potential moderating factors like age, sex, or smoking status.
Top 5 Most-Viewed MS Content of 2024
December 27th 2024

Top 5 Most-Viewed MS Content of 2024

Kyle Munz
The most-viewed pieces of multiple sclerosis (MS) content covered remeylination therapies, the potential of cannabis treatment, potential predictors of MS, and reliable telemedicine developments.
Frailty becomes more prevalent in aging populations; however, those affected by MS may exhibit more severe signs of frailty in earlier periods of their life compared to aging groups without MS | image credit: Anastasiia - stock.adobe.com
December 19th 2024

Exploring the Relationship Between MS and Frailty

Karen Jacobson-Sive
The rate of frailty among patients with multiple sclerosis (MS) ranges from 17% to 66% among ambulatory patients, and frailty among MS patients is linked to a host of complications.
ICYMI: Highlights From ACTRIMS 2024
December 12th 2024

ICYMI: Highlights From ACTRIMS 2024

Kyle Munz
Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).
Hamas' assault on Israel on October 7, 2023, was the deadliest attack on Jewish people this century | image credit: CYBERUSS - stock.adobe.com
December 11th 2024

October 7 Hamas Terrorist Attack Exacerbated MS Severity

Karen Jacobson-Sive
War-related psychological stress was associated with increased MRI-detected disease activity in patients with multiple sclerosis (MS).
covid-19 vaccine | Image credit: Leigh Prather - stock.adobe.com
December 1st 2024

Evaluating COVID-19 Vaccination Safety in Multiple Sclerosis

Kimberly Rath, PharmD
Researchers review the safety, efficacy, and considerations for COVID-19 vaccination in multiple sclerosis patients, especially those on disease-modifying therapies, affirming the vaccine's overall benefit in reducing severe COVID-19 risks without significantly increasing MS relapse rates.
3d illustration of a b cell-sebastianlaulitzki-stock.adobe.com.jpeg
November 29th 2024

sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

AJMC Contributor
The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.
Word Biomarkers next to a DNA strand | Image credit: iQoncept - stock.adobe.com
November 26th 2024

Researchers Outline Promising Biomarkers Throughout Course of MS

AJMC Contributor
As with other disease states, biomarkers that can provide value across diagnosis, prognosis, and treatment response, have been heavily sought out to help guide optimal treatment decisions throughout the course of disease.
BMI - Olivier Le Moal
November 21st 2024

Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link

Kimberly Rath, PharmD
A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Doctor examining MRI images of multiple sclerosis MS | Image Credit: © New Africa - stock.adobe.com
November 11th 2024

Lesion Repair, Damage Processes Correlate With MS Disease Characteristics

Jared Kaltwasser
New data suggest the frequency of damage and repair processes correlates with disease severity and disability in multiple sclerosis (MS).
Neurologic disease concept | image credit: ralwel - stock.adobe.com
November 9th 2024

Fexagratinib in MS Shows Promise for Human Use

Jared Kaltwasser
The therapy reduced inflammation and appeared to slow disease progression in models, suggesting it could have similar impacts in humans.
MS word cloud | Image Credit: © arloo-stock.adobe.com
November 8th 2024

Exploring Metabolic Links to Cognitive Impairment in MS

Gayle Turim Dickstein
The complex relationship between possibly impaired cognitive function in patients with multiple sclerosis (MS) and fasting blood sugar, fasting insulin, and insulin sensitivity levels is the focus of new work that advances understanding of intricate biological connections.
Fingolimod | Image Credit: © María Pilar Martínez - stock.adobe.com
October 26th 2024

Fingolimod-Induced Heart Rate Slowing Tied to Parasympathetic Dominance in MS

Jared Kaltwasser
New research helps explain why a subset of patients with relapsing/remitting multiple sclerosis (MS) experience long-term heart rate slowing after taking fingolimod.
MRI head brain scan | Image Credit: © DedMityay - stock.adobe.com
October 24th 2024

Brain Volume Loss Reductions Offer Comparative Tool for DMTs in Relapsing MS

Jared Kaltwasser
Various therapies have different impacts on brain volume loss in patients with relapsing multiple sclerosis (MS), a new study has found.
Support group image | Image Credit: © Rawpixel.com-stock.adobe.com
October 17th 2024

Reframing MS: The Role of Support Groups

Gayle Turim Dickstein
By attending multiple sclerosis (MS) support group meetings, getting to know members, and sharing their drug-company–sponsored meals, an author delves into the group’s culture and determination to resist being pigeonholed.
JT Lew, PharmD, MBA
October 1st 2024

Achieving the Goals of Value-Based Care for Multiple Sclerosis

Skylar Jeremias
Value-based agreements come with risks and benefits, but a health system’s existing facilities and initiatives can help support the goals associated with them, JT Lew, PharmD, MBA, a managed care pharmacist at MultiCare Health System, explained.
JT Lew, PharmD, MBA, managed care pharmacist at MultiCare Health System
September 24th 2024

How Payer Processes Can Impact MS Therapy Access: Dr JT Lew

Skylar Jeremias Rose McNulty
JT Lew, PharmD, MBA, managed care pharmacist at MultiCare Health System, spoke to the impacts of processes such as prior authorization and step therapy requirements in the realm of multiple sclerosis (MS).
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for RMS and PPMS. | Image Credit: BHM - stock.adobe.com
September 17th 2024

Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS

Rose McNulty
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
The eSDMT was developed to facilitate more frequent cognitive assessments for people with multiple sclerosis. | Image credit: fizkes - stock.adobe.com
September 12th 2024

Remote Test Reliably Assesses Cognitive Function in MS

Rose McNulty
An electronic version of the Symbol-Digit Modalities Test could enable people with multiple sclerosis (MS) to perform frequent remote cognitive assessments independently.
The new results make HERCULES the first and only study to demonstrate reduced CDP in nrSPMS. | Image credit: Juan Gärtner - stock-adobe.com
September 3rd 2024

Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS

Rose McNulty
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS).
AJMC Q&A with JT Lew, PharmD, MBA | Background image credit: ipopba - stock.adobe.com
September 3rd 2024

Dr JT Lew Explores the Barriers to MS Medication Access

Skylar Jeremias
JT Lew, PharmD, MBA, highlights that the primary challenges for patients with multiple sclerosis (MS) in accessing prescribed medications include dealing with the shock of the diagnosis, navigating complex health plan benefits and out-of-pocket costs, and experiencing delays due to insurance barriers.
Doctor examining MRI images - New Africa - stock.adobe.com
August 21st 2024

Stable MRI in Multiple Sclerosis Reveals Relapses as Acute Clinical Events

Isabella Ciccone, MPH
Acute clinical events with stable MRI were more likely among patients with multiple sclerosis who had longer disease duration, received highly effective disease-modifying therapies, and who presented with fatigue.
Multiple sclerosis diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com
August 16th 2024

Novel Risk Stratification Tool Shows Promise in MS

Rose McNulty
A predictive tool considering disease duration, age at disease onset, age, and Expanded Disability Status Scale score estimated patients’ risk of transition to secondary progressive multiple sclerosis (MS).
The study suggests the codesigned EWWMS program filled a need for reliable and evidence-based nutrition information for patients with MS. | Image credit: Studio Romantic - stock.adobe.com
August 16th 2024

Online Interventions Can Improve Dietary Behaviors in People With MS

Rose McNulty
A codesigned online nutrition program could potentially fill a need for reliable and evidence-based nutrition information for patients with multiple sclerosis (MS).
Results demonstrate correlations between fatigue and walking speed and mobility among patients with multiple sclerosis. | Image credit: kieferpix - stock.adobe.com
Published: August 13th 2024 | Updated: August 14th 2024

Fatigue Linked With Reduced Walking Speed, Mobility in Multiple Sclerosis

Rose McNulty
Study results demonstrated significant correlations between fatigue and reductions in walking speed and mobility among patients with multiple sclerosis.
Healthy behaviors, especially regular exercise and a healthy diet, were associated with better patient-reported outcomes in multiple sclerosis. | Image credit: Daniel Vincek - stock.adobe.com
August 7th 2024

Healthy Lifestyle Behaviors Linked to Better MS Outcomes

Rose McNulty
Engaging with healthy lifestyle behaviors, including a healthy diet and physical activity, was associated with better outcomes among patients with multiple sclerosis (MS).
12345678
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo